Danaher’s $5.7bn acquisition of Abcam faces stand-off with founder

Abcam’s $5.7bn acquisition by multi-national conglomerate Danaher may be blocked by shareholders after the company’s founder declared his intention to vote against the deal. Jonathan Milner, founder and ex-CEO of the UK-based antibody and protein manufacturer, announced yesterday (14 September) that he believed the $24 per share pricing “substantially undervalues” the company, and called for a replacement of the company’s board.